Compounds > canertinib
Page last updated: 2024-09-04

canertinib and crizotinib

canertinib has been researched along with crizotinib in 6 studies

Compound Research Comparison

Studies
(canertinib)		Trials
(canertinib)		Recent Studies (post-2010)
(canertinib)		Studies
(crizotinib)		Trials
(crizotinib)		Recent Studies (post-2010) (crizotinib)
1249651,7801121,718

Protein Interaction Comparison

ProteinTaxonomycanertinib (IC50)crizotinib (IC50)
Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2Homo sapiens (human)5.5
Tyrosine-protein kinase JAK2Homo sapiens (human)0.027
Sodium-dependent phosphate transport protein 2BHomo sapiens (human)0.051
Tyrosine-protein kinase ABL1Homo sapiens (human)0.5915
Tyrosine-protein kinase ABL1Mus musculus (house mouse)1.159
Epidermal growth factor receptorHomo sapiens (human)0.681
HLA class II histocompatibility antigen gamma chainHomo sapiens (human)0.0039
High affinity nerve growth factor receptorHomo sapiens (human)0.2905
Insulin receptorHomo sapiens (human)1.0966
Tyrosine-protein kinase LckHomo sapiens (human)1.8277
NucleophosminHomo sapiens (human)0.051
Insulin-like growth factor 1 receptorHomo sapiens (human)0.143
Hepatocyte growth factor receptorHomo sapiens (human)0.0057
Proto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)0.5458
Tyrosine-protein kinase JAK1Homo sapiens (human)0.563
Non-receptor tyrosine-protein kinase TYK2Homo sapiens (human)1.269
Tyrosine-protein kinase receptor UFOHomo sapiens (human)0.2223
Tyrosine-protein kinase JAK3Homo sapiens (human)1.36
ALK tyrosine kinase receptorMus musculus (house mouse)0.08
Angiopoietin-1 receptorHomo sapiens (human)0.2265
Angiopoietin-1 receptorMus musculus (house mouse)0.448
Macrophage-stimulating protein receptorHomo sapiens (human)0.25
BDNF/NT-3 growth factors receptorHomo sapiens (human)0.2005
Macrophage-stimulating protein receptorMus musculus (house mouse)0.08
Mitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)0.8745
Echinoderm microtubule-associated protein-like 4Homo sapiens (human)0.6542
ALK tyrosine kinase receptorHomo sapiens (human)0.4828

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Bharate, SB; Raghuvanshi, R1
de Bont, ES; den Dunnen, WF; Diks, SH; Hoving, EW; Lourens, HJ; Meeuwsen-de Boer, T; Plasschaert, SL; Zomerman, WW1
Bhargava, R; Chen, ZH; Hamilton, R; Liu, S; Luketich, JD; Luo, JH; Michalopoulos, GK; Monga, SP; Nalesnik, M; Nelson, JB; Pennathur, A; Tao, J; Tseng, G; Yu, YP1

Other Studies

6 other study(ies) available for canertinib and crizotinib

ArticleYear
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases

2022
Exogenous HGF Bypasses the Effects of ErbB Inhibition on Tumor Cell Viability in Medulloblastoma Cell Lines.
    PloS one, 2015, Volume: 10, Issue:10

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Hepatocyte Growth Factor; Humans; Medulloblastoma; Morpholines; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Signal Transduction

2015
MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice.
    Gastroenterology, 2017, Volume: 153, Issue:4

    Topics: alpha-Mannosidase; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Crizotinib; Dose-Response Relationship, Drug; Enzyme Activation; ErbB Receptors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Fusion; Golgi Apparatus; Humans; Liver Neoplasms; Mice; Mice, Knockout; Mice, SCID; Morpholines; Neoplasm Invasiveness; Neoplasm Transplantation; NIH 3T3 Cells; Oncogene Proteins, Fusion; Oncogenes; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; PTEN Phosphohydrolase; Pyrazoles; Pyridines; RNA Interference; Time Factors; Transfection; Tumor Burden

2017